Background: Differentiation of lymphocytic-plasmacytic enteropathy (LPE) from small cell lymphoma (SCL) in cats can be challenging. Hypothesis/Objective: Histology-guided mass spectrometry (HGMS) is a suitable method for the differentiation of LPE from SCL in cats.
| INTRODUCTION
Chronic enteropathy (CE) is the most common gastrointestinal disorder in older cats, with a rising prevalence over the past decade. 1 The disorder mostly comprises lymphocytic-plasmacytic enteropathy (LPE) and small cell lymphoma (SCL). 2 Routine work-up for cats with CE often includes the collection of biopsy specimens and the histopathologic evaluation of formalin-fixed paraffin-embedded (FFPE), hematoxylin and eosin (H&E)-stained tissue sections. 3, 4 Immunohistochemistry (IHC) with stains specific for T-and B-cells, as well as clonality assays, is considered state of the art by some authors. 4, 5 However, the specificity of polymerase chain reaction (PCR)based clonality tests has been questioned 6, 7 and some consider a combination of histopathology and immunohistochemistry as the gold standard. 8 The sensitivity and specificity of clonality assays in human and veterinary medicine vary widely with sensitivities between 70.0 and 97.6% and specificities between 54.3-98.7%. 7, [9] [10] [11] [12] [13] [14] [15] These wide ranges are the result of a combination of technical and biological variability. 16 Because of the inherently high error rate for clonality assays, there are rigorous preanalytical, analytical, and postanalytical standards published in human medicine under the EuroClonality/BIOMED-2 clonality standardization group guidelines. 16, 17 However, there are no standards for the conduction of clonality assays in veterinary medicine. 5, 18 To the authors' knowledge, there are no published data on the sensitivity and specificity of PCR-based clonality assays conducted on FFPE tissue from cats with either LPE or SCL.
Histology-guided mass spectrometry (HGMS) profiling is a proprietary application of matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) that employs histopathologic annotations for the targeted analysis of endogenous molecules from specific cell subpopulations. 19 This technology utilizes a machine learning algorithm to statistically assess the distribution of targeted biomolecules, such as proteins, lipids, or metabolites, to differentiate molecular signatures of specific disease states. 19 The ability of HGMS to distinguish between different diseases has been well demonstrated in animal models, and this technique has been successfully applied in human medicine to differentiate benign nevi from malignant melanoma. [20] [21] [22] The aim of this retrospective study was to investigate HGMS as a potential new tool for the differential diagnosis of SCL from LPE. We hypothesized that HGMS profiling of FFPE duodenal tissue samples and machine learning could be employed to develop a classification algorithm to distinguish proteomic signatures of lymphocytic-plasmacytic inflammatory lesions and SCL in cats. In addition, we compared the performance of PCR for antigen receptor rearrangements (PARR) and HGMS for the differentiation of SCL from LPE in cats with CE. 
| MATERIALS AND METHODS

| Sample cohort
| Panel evaluation
| Histology-guided mass spectrometry
An HGMS workflow overview is shown in Figure 1 . Two serial 5-μm, duodenal tissue sections were cut from FFPE biopsy specimen blocks. F I G U R E 1 HGMS workflow: A, sample processing-FFPE embedding and cutting of 5-μm serial tissue sections; B, sample preparation-paraffin removal, antigen retrieval, trypsin digestion, and MALDI matrix application; C, annotation-anatomic pathologist marks 50-μm diameter annotations of lymphocyte cell subpopulations on H&E image; D, image overlay-digital images of prepped slide and annotated H&E image are merged to teach mass spectrometer locations for analysis; E, sample analysis-proteomic data acquired by HGMS in MALDI mass spectrometer; F, data analysis-for algorithm development, machine learning is used to generate classification algorithm; for unknown sample assessment, classification algorithm is used to classify sample as SCL or LPE. FFPE, formalin-fixed paraffin-embedded; H&E, hematoxylin and eosin; HGMS, histology-guided mass spectrometry; LPE, lymphocytic-plasmacytic enteropathy; MALDI, matrix-assisted laser desorption ionization; SCL, small cell lymphoma
| Algorithm development and statistical analysis
Data from biopsy specimens were loaded into SCiLS Lab Pro 2019c (Bruker Daltonics) and preprocessed via baseline correction and normalization. Data were exported and processed in R studio for the selection of discriminatory mass spectral peaks. The peak list was transferred to SCiLS Lab Pro, and samples were tagged to belong to There was no significant difference between the major demographic characteristics, age, and sex between the training set and the validation set.
| Initial histopathological diagnoses
On the basis of evaluation of the 39 H&E-stained duodenal biopsy specimens comprising the training set, a diagnosis of SCL or suspected SCL was reached in 20 cases. In 19 cases, the pathologist found LPE (1 minimal to mild, 2 mild, 5 mild to moderate, 8 moderate, 2 moderate to severe, 1 mild LPE with marked lymphocytic epitheliotropism).
Histopathological evaluation of 54 biopsy specimens in the validation set, revealed a diagnosis of LPE in 26 cats (4 mild, 8 mild to moderate, 13 moderate, 1 moderate to severe). Twenty-seven cats were diagnosed with SCL or received a diagnosis of suspected SCL.
One cat was diagnosed with a medium cell lymphoma. Tables S1 and S2 show the complete list of histopathological diagnoses for the training set and validation set, respectively. 
| Validation set
The optimized LDA algorithm for the HGMS test was applied to an independent set of 54 biopsy samples (30 SCL and 24 LPE) to assess the classification accuracy of the model relative to the consensus diagnoses from the review panel. 
| PARR results
Of the 54 cats assigned to the validation data set, 34 were clonal on FFPE sections from duodenal tissue biopsy specimens, whereas 8 were histological studies, microbial identification, and biomarker discovery. 21, 22, 25 As a special application of MSI, HGMS integrates pathologist annotations within the mass spectrometry workflow to selectively look at histologically relevant cell subpopulations. This technology can be applied to both fresh frozen and FFPE tissues, and it is also suitable for tissue microarrays. Histology-guided mass spectrometry can be used in either a targeted manner, where the molecular target is known, such as in the differentiation of different protein isoforms or for pharmacological studies, or in an untargeted manner where the emphasis is on the detection of a mass spectral peak pattern consisting of differentially expressed molecules between samples. 19, 26 This approach is often referred to as mass spectral fingerprinting. With the application of HGMS, mass spectral profiles are collected from each annotation site in a tissue sample and statistically assessed by a machine learning algorithm to identify differences in peak intensities that are indicative of specific molecules. An HGMS classification algorithm therefore relies on the signature mass spectral fingerprints instead of individual biomarkers for disease classification. This technology is used in human medicine, for the differentiation of benign nevi from malignant melanoma which, similar to cats with CE, can pose a diagnostic challenge for pathologists with a high interobserver variability. [20] [21] [22] 27 Stages of biomarker discovery commonly involve the discovery and identification of biomarkers within a training set, and the validation of the assay using an independent set of samples. 28, 29 In the initial stages of assay development, samples should be well characterized. In the light of a lacking gold standard for the diagnosis and differentiation of LPE from SCL in cats, this study used the decisions of a panel of experts consisting of board-certified anatomic pathologists, internists, and oncologists. The members of the consensus panel were blinded as to the results of HGMS. Some of the consensus diagnoses served as a standard for selection of samples to comprise the training set that was used to develop the classification algorithm, along with previously classified samples. Also, the consensus diagnoses served as a benchmark against which relative test parameters were calculated in the validation set. This multidisciplinary approach is commonly used in human medicine, especially in the field of oncology, where tumor boards are considered good clinical practice and are recommended by the National Comprehensive Cancer Network guidelines. 30 Tumor boards consist of different experts who participate to provide balanced consensus opinions on the diagnostic and treatment plans for patients with complex cancer diagnoses. 31 A multidisciplinary approach is also explicitly recommended by the current EuroClonality/BIOMED-2 group, F I G U R E 4 Positive (A) and negative (B) predictive values for the HGMS and PARR methods as function of different disease prevalence. HGMS, histologyguided mass spectrometry; PARR, polymerase chain reaction for antigen receptor rearrangements who is dedicated to the standardization of clonality assays in human medicine. 16, 17 The EuroClonality/BIOMED-2 group was founded in response to a high interassay and intraassay variability and in an attempt to provide analytical 17 as well as preanalytical and postanalytical standards for the conduction and interpretation of clonality assays. 16 However, despite these extensive efforts, clonality assays in human medicine have been shown to have a multitude of pitfalls 32 with a recent study reporting a specificity as low as 54.3% for the T-cell receptor assay. 7 There is currently no standardization of clonality assays in veterinary medicine. Clonality assays in healthy cats with similar demographic characteristics to cats with CE revealed that the specificity of clonality assays for the detection of SCL in veterinary medicine might be of equal concern. 6 Clonality assays can reveal positive results in the absences of malignancy in many instances, such as benign clonal expansions, pseudoclonality, and oligoclonality, and with false-positive results. 5, 17 False-negative results can occur because of insufficient primer coverage or with a polyclonal (ie, inflammatory) background. 5, 17 Therefore, the guidelines by the EuroClonality/ BIOMED-2 group state that results of molecular clonality studies should always be interpreted in the context of the clinical, morphological, and immunophenotypic diagnosis, and in close collaboration with different experts in the field. 17 These recommendations were reflected in the study design of the current study. Relative to the panel consensus diagnoses for the validation set cases, HGMS demonstrated a sensitivity of 86.7% (95% CI: 74.5%-98.8%), a specificity of 91.7% (95% CI: 80.6%-100%), and an overall accuracy of 88.9% (95% CI: 80.5%-97.3%).
When comparing results of HGMS and results of PARR analysis for the validation set cases, HGMS showed superior test parameters relative to the panel consensus. Relative to the panel consensus diagnoses for the validation set cases, PARR exhibited a sensitivity of 85.7% (95% CI: 72.8%-98.7%), a specificity of 33.3% (95% CI: 14.5%-52.2%), and an overall accuracy of 61.5% (95% CI: 48.3%-74.8%).
Even though the true disease prevalence in a tested population of cats with CE is usually unknown, we calculated the positive and negative predictive values for HGMS and PARR as a function of true disease prevalence ( Figure 4 ). Results showed that in this cohort of cats, HGMS generally showed more favorable results compared to PARR.
Our study has several limitations. Given the retrospective nature of the study, procedures around the collection of intestinal biopsies were not standardized. However, this reflects the true conditions under which a test for the differentiation of SCL from LPE has to perform. This concept is further supported by recent studies showing, that standardization is a major source of poor reproducibility in preclinical trials. 33, 34 Despite best efforts, follow-up information was not available for all cases. However, the median survival time of cats with SCL can be substantial, 35 hence follow-up information might only allow for very limited conclusions.
Even though tumor boards are considered to be the good clinical practice by the National Comprehensive Cancer Network as well as the EuroClonality/BIOMED-2 group, expert opinion is not equal to evidence, leading to a degree of uncertainty for results in this study. However, in the authors' opinion, this approach is the best possible compromise in the absence of a true gold standard for the differentiation of LPE and SCL. Some samples were removed from the analysis because of a lack of consensus between the panelists. Any test for the differentiation of LPE from SCL is likely to be most useful using samples that are considered equivocal based on histopathology evaluations. Therefore, removing samples from the analysis that are equivocal may have led to biased results. However, the authors have undertaken every effort to mitigate this bias. Laboratory tests should always be developed on the full range of the disease spectrum and limiting the test development to a specific population can also severely bias test results. 36 
